Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Pediatric Neurology · Cerebral X-Linked Adrenoleukodystrophy (cALD) and Wiskott-Aldrich Syndrome (WAS)

Specific Condition Deep-Dive: cALD & WAS (Metabolic and Platelet-Driven Types)

At a Glance

Early surveillance is crucial: cALD brain MRI and adrenal testing can find treatable changes before symptoms, while WAS is signaled by low counts of unusually small platelets and may lead to early transplant or gene therapy considerations.

While XMEN and XLP are primarily “immune-driven,” cALD and WAS involve different core problems: one is a metabolic crisis in the brain, and the other is a defect in the body’s “bricks” and “glue”—the cells that prevent bleeding and fight infection [1][2].

cALD: The Race Against Time in the Brain

Cerebral X-linked Adrenoleukodystrophy (cALD) is caused by a mutation in the ABCD1 gene. This gene encodes a peroxisomal transporter that helps the body process Very Long Chain Fatty Acids (VLCFAs) [1]. Without a working ABCD1 gene, these fats build up to toxic levels, contributing to the destruction of myelin—the protective insulation around nerve cells in the brain [3][4].

The Necessity of MRI Surveillance

In cALD, symptoms like vision loss or trouble walking only appear after significant brain damage has already occurred [5]. An expert ALD team will individualize the surveillance schedule based on current guidelines (for instance, MRIs every 6 months during high-risk childhood years, and annually later). The use of contrast is determined by prior findings [6].

These MRIs look for the first tiny spots of myelin loss. Doctors use the Loes score, a rating from 0 to 34, to measure this damage [7]. A score of 0 is a healthy brain. Treatment is most successful when the Loes score is low (typically below 9) and the patient has no symptoms [8][9]. Once the score rises or symptoms appear, the “window of opportunity” for life-saving treatments like stem cell transplant or gene therapy (Skysona) may close [10][11].

The Adrenal Risk

Boys with this mutation face a cumulative risk of developing Adrenal Insufficiency (Addison’s disease), where the body cannot make enough “stress hormones” like cortisol [12]. This can be life-threatening during a simple flu or injury. Regular blood tests for ACTH and cortisol are essential, and patients must have a prescribed stress-dose hydrocortisone plan [13][12].

WAS: The Platelet and Immune Challenge

Wiskott-Aldrich Syndrome (WAS) is caused by a mutation in the WAS gene, which is vital for the “skeleton” of your blood and immune cells [14].

The “Small Platelet” Clue

While many conditions cause a low number of platelets, WAS is unique because the platelets are also unusually small (microthrombocytopenia) [15]. Because these tiny platelets don’t work well, patients have a high risk of:

  • Easy Bleeding: Bloody stools, nosebleeds, or internal bleeding [2].
  • Neurologic Risks: The most serious risk is intracranial hemorrhage (bleeding in the brain), which can be fatal if not managed [16].

The Classic Triad and Beyond

WAS is traditionally known for a “triad” of symptoms: eczema, low platelets, and frequent infections [2]. However, the disorder also makes the immune system “confused,” leading to autoimmunity, where the body attacks its own healthy cells [17].

Modern Treatment Options

For both conditions, waiting for severe symptoms to appear is dangerous.

  • For cALD: If an MRI shows early damage, a stem cell transplant or the newer gene therapy (Skysona) can arrest the progression of the disease [18][19]. (Note: HSCT and gene therapy carry substantial risks and do not reverse established injury or adrenal insufficiency).
  • For WAS: Stem cell transplant is the standard cure, with strong survival ranges in early intervention [20]. For those without a perfect donor match, gene therapy is an alternative that has shown success in clearing eczema and stopping severe infections, subject to jurisdiction-specific availability [21][22]. Early detection through newborn screening (which is jurisdiction-dependent) or family history is the most powerful tool [13][23].

Common questions in this guide

Why are regular brain MRIs important for cALD?
Cerebral X-linked adrenoleukodystrophy can damage the brain’s myelin before vision, walking, or behavior changes are noticeable. Regular MRI scans can detect early changes while treatments such as a stem cell transplant or gene therapy may still have the best chance of slowing progression.
What does the Loes score tell us about cALD?
A Loes score from 0 to 34 estimates the extent of brain changes seen on MRI, with 0 indicating no measurable damage. A lower score, often below 9, and no symptoms are associated with the best treatment window, but the care team must interpret the score with symptoms and other MRI findings.
How is adrenal insufficiency checked in someone with cALD?
Doctors commonly monitor ACTH and morning cortisol to look for adrenal insufficiency. Families should have an individualized stress-dose hydrocortisone plan for illness or injury because the body may not produce enough cortisol during stress.
What blood test clue points to Wiskott-Aldrich syndrome?
WAS usually causes a low platelet count with platelets that are unusually small, a finding called microthrombocytopenia. Platelet count and mean platelet volume, or MPV, together with bleeding, eczema, infections, and other immune findings, help clinicians evaluate the diagnosis.
What treatments may be considered for cALD and WAS?
For cALD, early MRI changes may lead an expert team to consider a stem cell transplant or gene therapy such as Skysona for eligible patients. For WAS, a stem cell transplant is a standard potentially curative treatment, while gene therapy may be an alternative for some patients where it is available; both approaches have important risks and eligibility requirements.
How much does early treatment matter in these disorders?
Waiting until severe symptoms appear can reduce treatment options. cALD treatments work best before major brain injury, and early WAS treatment can reduce the risk of serious bleeding and infections; established brain injury or adrenal insufficiency may not be reversed by transplant or gene therapy.

Get notified when new evidence is published on X-linked immunoneurologic disorder.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (23)
  1. 1

    Structural insights into substrate recognition and translocation of human peroxisomal ABC transporter ALDP.

    Xiong C, Jia LN, Xiong WX, et al.

    Signal transduction and targeted therapy 2023; (8(1)):74 doi:10.1038/s41392-022-01280-9.

    PMID: 36810450
  2. 2

    Clinical Manifestations and Pathophysiological Mechanisms of the Wiskott-Aldrich Syndrome.

    Candotti F

    Journal of clinical immunology 2018; (38(1)):13-27 doi:10.1007/s10875-017-0453-z.

    PMID: 29086100
  3. 3

    Structures of the human peroxisomal fatty acid transporter ABCD1 in a lipid environment.

    Le LTM, Thompson JR, Dang PX, et al.

    Communications biology 2022; (5(1)):7 doi:10.1038/s42003-021-02970-w.

    PMID: 35013584
  4. 4

    25-hydroxycholesterol contributes to cerebral inflammation of X-linked adrenoleukodystrophy through activation of the NLRP3 inflammasome.

    Jang J, Park S, Jin Hur H, et al.

    Nature communications 2016; (7()):13129 doi:10.1038/ncomms13129.

    PMID: 27779191
  5. 5

    Presymptomatic Lesion in Childhood Cerebral Adrenoleukodystrophy: Timing and Treatment.

    Mallack EJ, Van Haren KP, Torrey A, et al.

    Neurology 2022; (99(5)):e512-e520 doi:10.1212/WNL.0000000000200571.

    PMID: 35609989
  6. 6

    MRI surveillance of boys with X-linked adrenoleukodystrophy identified by newborn screening: Meta-analysis and consensus guidelines.

    Mallack EJ, Turk BR, Yan H, et al.

    Journal of inherited metabolic disease 2021; (44(3)):728-739 doi:10.1002/jimd.12356.

    PMID: 33373467
  7. 7

    Neurocognitive Trajectory of Boys Who Received a Hematopoietic Stem Cell Transplant at an Early Stage of Childhood Cerebral Adrenoleukodystrophy.

    Pierpont EI, Eisengart JB, Shanley R, et al.

    JAMA neurology 2017; (74(6)):710-717 doi:10.1001/jamaneurol.2017.0013.

    PMID: 28418523
  8. 8

    Survival and Functional Outcomes in Boys with Cerebral Adrenoleukodystrophy with and without Hematopoietic Stem Cell Transplantation.

    Raymond GV, Aubourg P, Paker A, et al.

    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2019; (25(3)):538-548 doi:10.1016/j.bbmt.2018.09.036.

    PMID: 30292747
  9. 9

    Variables affecting outcomes after allogeneic hematopoietic stem cell transplant for cerebral adrenoleukodystrophy.

    Chiesa R, Boelens JJ, Duncan CN, et al.

    Blood advances 2022; (6(5)):1512-1524 doi:10.1182/bloodadvances.2021005294.

    PMID: 34781360
  10. 10

    Intensity of MRI Gadolinium Enhancement in Cerebral Adrenoleukodystrophy: A Biomarker for Inflammation and Predictor of Outcome following Transplantation in Higher Risk Patients.

    Miller WP, Mantovani LF, Muzic J, et al.

    AJNR. American journal of neuroradiology 2016; (37(2)):367-72 doi:10.3174/ajnr.A4500.

    PMID: 26427835
  11. 11

    Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy.

    Eichler F, Duncan C, Musolino PL, et al.

    The New England journal of medicine 2017; (377(17)):1630-1638 doi:10.1056/NEJMoa1700554.

    PMID: 28976817
  12. 12

    X-linked adrenoleukodystrophy and primary adrenal insufficiency.

    Cappa M, Todisco T, Bizzarri C

    Frontiers in endocrinology 2023; (14()):1309053 doi:10.3389/fendo.2023.1309053.

    PMID: 38034003
  13. 13

    Adrenoleukodystrophy in the Differential Diagnosis of Boys Presenting with Primary Adrenal Insufficiency without Adrenal Antibodies

    Ryalls MR, Gan HW, Davison JE

    Journal of clinical research in pediatric endocrinology 2021; (13(2)):212-217 doi:10.4274/jcrpe.galenos.2020.2020.0214.

    PMID: 32394691
  14. 14

    Splenectomy revisited in Wiskott-Aldrich syndrome in the era of HSCT and gene therapy: a bridge, a rescue, or simply obsolete?

    Khanafer Y, Al-Naemi A, Khayyat L, Cyprian F

    Frontiers in immunology 2026; (17()):1851771 doi:10.3389/fimmu.2026.1851771.

    PMID: 42558364
  15. 15

    Gene Correction of Wiskott-Aldrich syndrome iPS Cells Rescues Proplatelet Defects and Improves Platelet Size.

    Ingrungruanglert P, Phodang S, Amarinthnukrowh P, et al.

    Thrombosis and haemostasis 2025; (125(11)):1115-1126 doi:10.1055/a-2508-0983.

    PMID: 39719152
  16. 16

    Neurological manifestations in Wiskott-Aldrich syndrome: a systematic review.

    Raccagni NG, Milanesi VF, Lucchini G, et al.

    Frontiers in immunology 2026; (17()):1829058 doi:10.3389/fimmu.2026.1829058.

    PMID: 42183254
  17. 17

    Autoimmunity in Wiskott-Aldrich Syndrome: Updated Perspectives.

    Sudhakar M, Rikhi R, Loganathan SK, et al.

    The application of clinical genetics 2021; (14()):363-388 doi:10.2147/TACG.S213920.

    PMID: 34447261
  18. 18

    Newborn Screening for X-Linked Adrenoleukodystrophy in Nebraska: Initial Experiences and Challenges.

    Baker CV, Cady Keller A, Lutz R, et al.

    International journal of neonatal screening 2022; (8(2)) doi:10.3390/ijns8020029.

    PMID: 35645283
  19. 19

    Hematopoietic stem cell therapy and ex vivo gene therapy for X-linked adrenoleukodystrophy.

    Eichler FS, Kuehl JS

    Handbook of clinical neurology 2024; (202()):265-278 doi:10.1016/B978-0-323-90242-7.00018-3.

    PMID: 39111913
  20. 20

    Hematopoietic Stem Cell Therapy for Wiskott-Aldrich Syndrome: Improved Outcome and Quality of Life.

    Mallhi KK, Petrovic A, Ochs HD

    Journal of blood medicine 2021; (12()):435-447 doi:10.2147/JBM.S232650.

    PMID: 34149291
  21. 21

    From oncogenesis to approval: the lentiviral gene therapy revolution in Wiskott-Aldrich syndrome.

    Karimizadeh Z, Kalantari A, Behfar M, et al.

    Regenerative medicine 2026; (21(8-9)):519-528 doi:10.1080/17460751.2026.2741431.

    PMID: 42856044
  22. 22

    Outcomes of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome.

    Labrosse R, Chu JI, Armant MA, et al.

    Blood 2023; (142(15)):1281-1296 doi:10.1182/blood.2022019117.

    PMID: 37478401
  23. 23

    Comprehensive clinical and immunologic characterization of Wiskott-Aldrich syndrome in Iran: a 10-year cohort study.

    Esmaeilzadeh H, Gholami MA, Dehghani SS, et al.

    BMC immunology 2025; (26(1)):97 doi:10.1186/s12865-025-00779-4.

    PMID: 41345550

This page is for informational purposes about cALD and WAS and does not constitute medical advice. An ALD, neurology, hematology, or immunology team should interpret each patient’s MRI, hormone tests, platelet results, and treatment options.

Guide contents X-linked immunoneurologic disorder
Research & Literature
04 Specific Condition Deep-Dive 06 Care Team, First Visit Prep, and Treatment Strategies